Restructuring, Integration and Other Charges

6 Months Ended

Jun. 28, 2026

Restructuring and Related Activities [Abstract]

Restructuring, Integration and Other Charges

Restructuring and other charges primarily include costs incurred in the three and six months ended June 28, 2026, in connection with the (i) implementation of cost-reduction, strategic productivity and margin improvement initiatives under the Optimization Plan and (ii) the SAVANNA Exit. The cumulative pre-tax charges to be incurred by the Company to implement the Optimization Plan are expected to be approximately $100.0 million through 2027, with charges of $28.1 million incurred to date. The SAVANNA Exit is expected to be substantially complete by the first half of 2027.

Integration expenses for the three and six months ended June 28, 2026 include costs incurred in connection with the acquisition of LEX Diagnostics. Integration expenses for the three and six months ended June 29, 2025 include costs incurred in connection with the Combinations, which have been completed at the end of 2025.

The following table summarizes Restructuring, integration and other charges:


	Three Months Ended				Six Months Ended
(In millions)	June 28, 2026		June 29, 2025		June 28, 2026		June 29, 2025
Restructuring charges:
Employee terminations	$	0.6	$	6.3	$	1.2	$	6.3
Asset impairments/write off	0.4		0.3		1.1		0.3


Provision for restructuring(1)(2)	1.0		6.6		2.3		6.6
SAVANNA Exit charges:
Employee terminations	0.1		1.0		0.3		1.0
Asset impairments/write off	(0.2)		148.6		(0.8)		148.6
Other	(1.6)		—		(1.2)		—
SAVANNA Exit charges(2)	(1.7)		149.6		(1.7)		149.6
Implementation costs(2)(3)	4.6		0.1		7.7		0.1
Accelerated depreciation	2.1		1.0		4.1		1.0
Integration expenses(2)	2.6		22.6		2.6		38.7
Total charges	$	8.6	$	179.9	$	15.0	$	196.0

Cost of sales, excluding amortization of intangibles	$	2.1	$	1.0	$	4.1	$	1.0


Restructuring, integration and other charges	6.5		178.9		10.9		195.0
Total charges	$	8.6	$	179.9	$	15.0	$	196.0

(1) Primarily represents charges incurred in connection with the Raritan, NJ site exit. The manufacturing activities conducted in the Raritan, NJ facility will be transferred to other facilities.

(2) Included in the Restructuring, integration and other charges in the Consolidated Statements of Loss.

(3) Represents incremental costs directly related to implementing cost-reduction, strategic productivity and margin improvement initiatives.

The components of, and charges in, the restructuring accruals were as follows:


(In millions)	Employee Terminations		Asset impairments/write off		Accrual
Balance at December 28, 2025	$	7.6	$	—	$	7.6
Provision for restructuring	1.2		1.1		2.3
Utilization and other	(1.1)		(1.1)		(2.2)
Balance at June 28, 2026 (1)	$	7.7	$	—	$	7.7

(1) Included in Other current liabilities ($0.1 million) and Other liabilities ($7.6 million)